Status:
COMPLETED
Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
Estimate the effect of oral ketoconazole administration (400 mg once daily over 3 days) on the pharmacokinetics (process by which the drug is absorbed, distributed, metabolized, and eliminated by the ...
Eligibility Criteria
Inclusion
- Healthy male and/or female (non-childbearing potential) subjects between the ages of 18 and 55 years
Exclusion
- Clinically significant disease
- Recent history of serious infection
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01202240
Start Date
September 1 2010
End Date
September 1 2010
Last Update
February 17 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Brussels, Belgium, B-1070